SOUTH SAN FRANCISCO, Calif., March 02, 2017 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 9, 2017 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2016.
The call can be accessed by dialing (844) 269-7720 (U.S. and Canada) or (574) 990-1148 (international), and entering passcode 59899543.
To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Instagram Outage Disrupts Thousands of U.S. Users
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



